4 - ContextLogic Inc. (0001822250) (Issuer)

4 - ContextLogic Inc. (0001822250) (Issuer)

4 - ContextLogic Inc. (0001822250) (Issuer)

4 - ContextLogic Inc. (0001822250) (Issuer)

4 - LogicBio Therapeutics, Inc. (0001664106) (Issuer)

4 - LogicBio Therapeutics, Inc. (0001664106) (Issuer)

4 - LogicBio Therapeutics, Inc. (0001664106) (Issuer)

4 - LogicBio Therapeutics, Inc. (0001664106) (Issuer)

4 - LogicBio Therapeutics, Inc. (0001664106) (Issuer)

4 - LogicBio Therapeutics, Inc. (0001664106) (Issuer)

LEXINGTON, Mass., March 4, 2022 /PRNewswire/ -- LogicBio® Therapeutics, Inc. (NASDAQ:LOGC), a clinical-stage genetic medicine company, today reported financial results for the year ended December 31, 2021, and provided business updates. "At LogicBio, we are continuing to advance our mission to safely deliver novel genetic medicines to people impacted by devastating, early onset diseases," said Frederic Chereau, president and chief executive officer of LogicBio. "We are pleased to report that the serious adverse event experienced by the fourth patient enrolled in our Phase 1/2 SUNRISE trial of LB-001 in pediatric patients with methylmalonic acidemia has resolved." Recent Business Update

LEXINGTON, Mass., May 19, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced the promotion of Daniel Gruskin, MD, as chief medical officer. Dr. Gruskin most recently served as senior vice president and head of clinical development. The Company also announced the appointment of Stephen Boyer, PhD, as vice president of regulatory and quality affairs, and Peter Pechan, PhD, as vice president of gene therapy, who will support progress in the Phase I/II SUNRISE clinical trial of LB-001, the Company's investi

LEXINGTON, Mass., May 10, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced the appointment of Andrea Paul as general counsel and corporate secretary and Janice Olson as senior vice president of strategy and portfolio management. Ms. Paul and Ms. Olson are both seasoned industry experts with extensive experience in the pharmaceutical and biotechnology industries including in the gene therapy and rare disease sectors. "It is an exciting time at LogicBio with ongoing efforts to expand the reach of our G

As per the report by Visiongain, the Rare Diseases Market was valued at US$188.58 billion in 2022 and is projected to grow at a CAGR of 12.27% during the forecast period 2023-2033.  Visiongain has published a new report entitled Rare Diseases 2023-2033. It includes profiles of Rare Diseases and Forecasts Market Segment by Diseases (Cancer, Metabolic Diseases, Neurological Conditions, Hematologic Disorders, Infectious Diseases, Musculoskeletal Disorders, Cardiovascular Disorders, Others), Market Segment by Type (Non-biologics, Biologics), Market Segment by End-users (Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies), Market Segment by Age (Adult, Paediatric), plus COVID-19 Impact

Visiongain has published a new report entitled Rare Diseases 2023-2033. It includes profiles of Rare Diseases and Forecasts Market Segment by Diseases (Cancer, Metabolic Diseases, Neurological Conditions, Hematologic Disorders, Infectious Diseases, Musculoskeletal Disorders, Cardiovascular Disorders, Others), Market Segment by Type (Non-biologics, Biologics), Market Segment by End-users (Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies), Market Segment by Age (Adult, Paediatric), plus COVID-19 Impact Analysis and Recovery Pattern Analysis ("V"-shaped, "W"-shaped, "U"-shaped, "L"-shaped), Profiles of Leading Companies, Region and Country.  The rare diseases market was valued at

Visiongain has published a new report entitled Rare Diseases 2023-2033. It includes profiles of Rare Diseases and Forecasts Market Segment by Diseases (Cancer, Metabolic Diseases, Neurological Conditions, Hematologic Disorders, Infectious Diseases, Musculoskeletal Disorders, Cardiovascular Disorders, Others), Market Segment by Type (Non-biologics, Biologics), Market Segment by End-users (Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies), Market Segment by Age (Adult, Paediatric), plus COVID-19 Impact Analysis and Recovery Pattern Analysis ("V"-shaped, "W"-shaped, "U"-shaped, "L"-shaped), Profiles of Leading Companies, Region and Country.  The rare diseases market was valued a

LEXINGTON, Mass., Feb. 2, 2022 /PRNewswire/ -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a clinical-stage genetic medicine company, today provided an update on the LB-001 clinical development program. The U.S. Food and Drug Administration (FDA) has notified the company that its Phase 1/2 SUNRISE clinical trial of LB-001 in pediatric patients with methylmalonic acidemia (MMA) has been placed on clinical hold. The company will host a conference call and webcast this morning to discuss this update. To date, four patients have been dosed in the SUNRISE trial with LB-001, LogicBio's investigational, single-administration, adeno-associated virus (AAV) genome editing therapy. In accordance with th

Gainers JX Luxventure (NASDAQ:JXJT) shares increased by 13.3% to $1.7 during Thursday's regular session. The market value of their outstanding shares is at $10.3 million. Koss (NASDAQ:KOSS) shares increased by 9.59% to $11.65. The company's market cap stands at $107.8 million. Greenlane Hldgs (NASDAQ:GNLN) stock rose 7.27% to $0.29. The company's market cap stands at $1.1 million. Kirkland's (NASDAQ:KIRK) shares rose 4.99% to $1.68. The market value of their outstanding shares is at $21.9 million. Rent the Runway (NASDAQ:RENT) stock increased by 4.95% to $15.46. The company's market cap stands at $57.5 million. Losers ToughBuilt Industries (NASDAQ:TBLT) stock fell 10.8% to $4.47 duri

LogicBio Therapeutics (NASDAQ:LOGC) reported quarterly losses of $(0.18) per share. This is a 41.94 percent increase over losses of $(0.31) per share from the same period last year.

On Friday, shares of LogicBio Therapeutics, Inc. (NASDAQ:LOGC) experienced volatile short activity. After the activity, the stock price went up +0% to $2.07. The overall sentiment for LOGC has been Neutral. The signal from the volatility alert is trending Bearish. Therefore, the recommendation is to Increase Short Exposure. The volatility alert was produced on the prior trading date, 11/4/2022 with a volatility change of +102.26%. The current volatility indicator stands at 7.928. Overview: The securities lending volatility indicator is produced by Tidal Markets, in partnership with Benzinga Insights. Securities lending primarily serves the purpose of providing liquidity to short sellers.

-SEC Filing

Gainers LogicBio Therapeutics, Inc. (NASDAQ:LOGC) shares surged 637.6% to close at $2.01 on Monday after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2.07 per share. FedNat Holding Company (NASDAQ:FNHC) jumped 308.7% to close at $0.47 after dipping around 28% on Friday. Oblong, Inc. (NASDAQ:OBLG) gained 167% to settle at $0.40. Shares of several companies in the technology sector traded higher as stocks rebound following recent weakness. FingerMotion, Inc. (NASDAQ:FNGR) shares rose 92.9% to close at $6.50 after the stock rose more than 80% Friday. Wearable Devices Ltd. (NASDAQ:WLDS) gained 48.9% to close at $1.31 after declining around 8% on Fr

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite climbing more than 200 points on Monday. The Dow traded up 2.93% to 29,566.07 while the NASDAQ rose 2.56% to 10,846.26. The S&P 500 also rose, gaining, 2.85% to 3,687.75. Also check this: Nike, Lululemon, Dick's Sporting Goods And Other Big Losers From Friday Leading and Lagging Sectors Energy shares jumped by 4.9% on Monday. Leading the sector was strength from Ultrapar Participações S.A. (NYSE:UGP) and Amplify Energy Corp. (NYSE:AMPY). In trading on Monday, consumer discretionary shares rose by just 0.2%. Top Headline The ISM manufacturing PMI unexpectedly dropped to 50.9 in September, compared wi

Gainers LogicBio Therapeutics (NASDAQ:LOGC) shares increased by 641.3% to $2.02 during Monday's regular session. The current volume of 10.3 million shares is 5450.9% of LogicBio Therapeutics's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $66.5 million. Myovant Sciences (NYSE:MYOV) shares moved upwards by 38.78% to $24.93. Trading volume for Myovant Sciences's stock is 6.3 million as of 13:30 EST. This is 853.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $2.3 billion. Avenue Therapeutics (NASDAQ:ATXI) shares rose 31.16% to $13.22. The current volume of 13.8 mil

LogicBio Therapeutics's (NASDAQ:LOGC) short percent of float has fallen 62.5% since its last report. The company recently reported that it has 29 thousand shares sold short, which is 0.12% of all regular shares that are available for trading. Based on its trading volume, it would take traders 0.2 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Sho

Gainers LogicBio Therapeutics, Inc. (NASDAQ:LOGC) gained 641% to $2.0207 after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2.07 per share. FedNat Holding Company (NASDAQ:FNHC) jumped 223% to $0.3725 after dipping around 28% on Friday. FingerMotion, Inc. (NASDAQ:FNGR) shares gained 63.3% to $5.50 after the stock rose more than 80% Friday. Avenue Therapeutics, Inc. (NASDAQ:ATXI) gained 47.1% to $14.83. Myovant Sciences Ltd. (NYSE:MYOV) shares gained 36% to $24.43 after the company received an acquisition offer from Sumitovant Biopharma and Sumitormo Pharma to acquire the company for $22.75 per share in cash. Wearable Devices Ltd. (NASDAQ:WLDS)

U.S. stocks extended gains midway through trading, with the Dow Jones gaining more than 600 points on Monday. The Dow traded up 2.17% to 29,349.33 while the NASDAQ rose 1.72% to 10,757.76. The S&P 500 also rose, gaining, 2.03% to 3,658.58. Also check this: Nike, Lululemon, Dick's Sporting Goods And Other Big Losers From Friday Leading and Lagging Sectors Energy shares jumped by 4.4% on Monday. Leading the sector was strength from Ultrapar Participações S.A. (NYSE:UGP) and Petróleo Brasileiro S.A. - Petrobras (NYSE:PBR). In trading on Monday, consumer discretionary shares rose by just 0.1%. Top Headline The ISM manufacturing PMI unexpectedly dropped to 50.9 in September, compare

OAKLAND, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- ContextLogic Inc. (NASDAQ:LOGC), ("ContextLogic," the "Company," "we" or "our") today reported its financial results for the quarter and nine months ended September 30, 2024. Third Quarter 2024 Financial Highlights Net Loss: Net loss was $1 million, compared to a net loss of $80 million in the third quarter of 2023.As of September 30, 2024, the Company had $33 million in cash and cash equivalents, $117 million in marketable securities and $8 million in prepaid expenses and other current assets (primarily made up of $7 million in restricted cash). Company Outlook Over the last quarter, the Company has created a streamlined administrat

OAKLAND, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- ContextLogic Inc. (NASDAQ:LOGC), ("ContextLogic," the "Company," "we" or "our") today reported its financial results for the quarter and six months ended June 30, 2024. Company Update On February 10, 2024, the Company entered into an asset purchase agreement (the "Asset Purchase Agreement") with Qoo10 Inc., a Delaware corporation ("Qoo10 Delaware"), and, for certain specified purposes, Qoo10 Pte. Ltd., a Singapore private limited company and Qoo10 Delaware's parent company ("Qoo10"), pursuant to which (i) the Company agreed to sell substantially all of its assets to Qoo10 Delaware or an affiliate designated by Qoo10 Delaware (such desig

As per the report by Visiongain, the Rare Diseases Market was valued at US$188.58 billion in 2022 and is projected to grow at a CAGR of 12.27% during the forecast period 2023-2033.  Visiongain has published a new report entitled Rare Diseases 2023-2033. It includes profiles of Rare Diseases and Forecasts Market Segment by Diseases (Cancer, Metabolic Diseases, Neurological Conditions, Hematologic Disorders, Infectious Diseases, Musculoskeletal Disorders, Cardiovascular Disorders, Others), Market Segment by Type (Non-biologics, Biologics), Market Segment by End-users (Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies), Market Segment by Age (Adult, Paediatric), plus COVID-19 Impact

Visiongain has published a new report entitled Rare Diseases 2023-2033. It includes profiles of Rare Diseases and Forecasts Market Segment by Diseases (Cancer, Metabolic Diseases, Neurological Conditions, Hematologic Disorders, Infectious Diseases, Musculoskeletal Disorders, Cardiovascular Disorders, Others), Market Segment by Type (Non-biologics, Biologics), Market Segment by End-users (Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies), Market Segment by Age (Adult, Paediatric), plus COVID-19 Impact Analysis and Recovery Pattern Analysis ("V"-shaped, "W"-shaped, "U"-shaped, "L"-shaped), Profiles of Leading Companies, Region and Country.  The rare diseases market was valued at

Visiongain has published a new report entitled Rare Diseases 2023-2033. It includes profiles of Rare Diseases and Forecasts Market Segment by Diseases (Cancer, Metabolic Diseases, Neurological Conditions, Hematologic Disorders, Infectious Diseases, Musculoskeletal Disorders, Cardiovascular Disorders, Others), Market Segment by Type (Non-biologics, Biologics), Market Segment by End-users (Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies), Market Segment by Age (Adult, Paediatric), plus COVID-19 Impact Analysis and Recovery Pattern Analysis ("V"-shaped, "W"-shaped, "U"-shaped, "L"-shaped), Profiles of Leading Companies, Region and Country.  The rare diseases market was valued a

LogicBio acquisition to build on current collaborations and advancements in genomic medicine Alexion, AstraZeneca Rare Disease, today announced the completion of its acquisition of LogicBio® Therapeutics, Inc. (NASDAQ:LOGC), a pioneering genomic medicine company. The acquisition creates an opportunity to accelerate Alexion's growth in genomic medicines through unique technology, an experienced rare disease R&D team, and expertise in pre-clinical development. Frederic Chereau, CEO of LogicBio, will join Alexion as Senior Vice President, Strategy and Business Development. Additional Transaction Details The tender offer for all of the issued and outstanding shares of common stock of LogicB

- Pre-clinical results published in PLOS ONE demonstrating a single intravenous administration of mLB-001 in neonatal or adult MMA mice correlated with prevention of severe weight loss and mortality when challenged with a high protein diet - Definitive merger agreement with Alexion, AstraZeneca Rare Disease, to acquire LogicBio with transaction   LEXINGTON, Mass., Nov. 14, 2022  /PRNewswire/ -- LogicBio® Therapeutics, Inc. (NASDAQ:LOGC), a clinical-stage genetic medicine company, today reported financial results for the third quarter ended September 30, 2022 and provided business updates. Recent Business Highlights: In August, LogicBio presented interim data from the SUNRISE Phase 1/2 trial

LogicBio acquisition to build on current collaborations and advancements in genomic medicine Alexion, AstraZeneca Rare Disease, today announced that it has entered a definitive agreement to acquire Lexington, Mass.-based LogicBio® Therapeutics, Inc. (NASDAQ:LOGC), a pioneering genomic medicine company. The proposed acquisition aims to rapidly accelerate Alexion's growth in genomic medicines through LogicBio's unique technology, experienced rare disease R&D team, and expertise in pre-clinical development. "The proposed acquisition of LogicBio is a significant development for our growing research in genomic medicine," said Marc Dunoyer, Chief Executive Officer, Alexion, AstraZeneca Rare Dis

LogicBio acquisition to build on current collaborations and advancements in genomic medicine LEXINGTON, Mass., Oct. 3, 2022 /PRNewswire/ -- LogicBio® Therapeutics, Inc. (NASDAQ:LOGC), a pioneering clinical-stage genomic medicine company, today announced that it has entered into a definitive agreement under which AstraZeneca Rare Disease will acquire LogicBio. The proposed acquisition brings LogicBio's unique technology, experienced rare disease R&D team, and expertise in pre-clinical development to support Alexion's growth in genomic medicines. Fred Chereau, President and Chief Executive Officer, LogicBio, said: "We are excited about the opportunity to bring our science and expertise in gene

Single intravenous administration of mLB-001 in neonatal or adult MMA mice correlated with prevention of severe weight loss and mortality when challenged with a high protein diet. LEXINGTON, Mass., Sept. 21, 2022 /PRNewswire/ -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a clinical-stage genetic medicine company, today announced that results from the company's preclinical research study entitled "Novel AAV-mediated genome editing therapy prevents metabolic decompensation in a mouse model of methylmalonic acidemia" have been published in the peer-reviewed journal PLOS ONE. MMA is a metabolic disorder most commonly caused by mutations in the methylmalonyl-CoA mutase (MMUT) gene. Patients with

10-Q - ContextLogic Inc. (0001822250) (Filer)

8-K - ContextLogic Inc. (0001822250) (Filer)

8-K - ContextLogic Inc. (0001822250) (Filer)

10-Q - ContextLogic Inc. (0001822250) (Filer)

8-K - ContextLogic Inc. (0001822250) (Filer)

144 - ContextLogic Inc. (0001822250) (Subject)

8-K - ContextLogic Inc. (0001822250) (Filer)

15-12G - LogicBio Therapeutics, Inc. (0001664106) (Filer)

EFFECT - LogicBio Therapeutics, Inc. (0001664106) (Filer)

S-8 POS - LogicBio Therapeutics, Inc. (0001664106) (Filer)